ArriVent BioPharma (AVBP) News Today $18.63 +0.24 (+1.31%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$17.15 -1.48 (-7.94%) As of 04:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period 41,921 Shares in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Bought by Wellington Management Group LLPWellington Management Group LLP purchased a new stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 41,921 shares of the company's stock, valued at approximately $1,April 15 at 3:30 AM | marketbeat.comVanguard Group Inc. Has $37.76 Million Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP)Vanguard Group Inc. raised its holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 5.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,417,291 shares of the company's stock after buying an additional 71,April 15 at 3:16 AM | marketbeat.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of "Buy" by BrokeragesArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) has been given an average recommendation of "Buy" by the six research firms that are presently covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the compaApril 15 at 1:09 AM | marketbeat.comArriVent Biopharma management to meet with OppenheimerApril 9, 2025 | markets.businessinsider.comArriVent BioPharma (NASDAQ:AVBP) Sets New 52-Week Low - What's Next?ArriVent BioPharma (NASDAQ:AVBP) Hits New 12-Month Low - Time to Sell?April 9, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Sees Strong Trading Volume - Should You Buy?ArriVent BioPharma (NASDAQ:AVBP) Sees Large Volume Increase - What's Next?April 6, 2025 | marketbeat.comSwiss National Bank Buys Shares of 26,400 ArriVent BioPharma, Inc. (NASDAQ:AVBP)Swiss National Bank purchased a new stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 26,400 shares of the company's stock, valued at approximately $703March 30, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Stock Price Up 2.2% - Here's WhyArriVent BioPharma (NASDAQ:AVBP) Trading 2.2% Higher - Time to Buy?March 29, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7% - Time to Sell?ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 4.7% - Should You Sell?March 26, 2025 | marketbeat.comIntech Investment Management LLC Acquires Shares of 14,798 ArriVent BioPharma, Inc. (NASDAQ:AVBP)Intech Investment Management LLC purchased a new stake in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 14,798 shares of the company's stock, valued at apprMarch 26, 2025 | marketbeat.comBrokers Offer Predictions for AVBP Q1 EarningsArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - B. Riley issued their Q1 2025 earnings per share (EPS) estimates for ArriVent BioPharma in a research note issued on Wednesday, March 19th. B. Riley analyst K. Patel forecasts that the company will post earnings of ($0.70) per share for the qMarch 24, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Raised to Strong-Buy at B. RileyB. Riley raised shares of ArriVent BioPharma to a "strong-buy" rating in a research report on Wednesday.March 22, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up - Still a Buy?ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up - Time to Buy?March 21, 2025 | marketbeat.comLatest ArriVent BioPharma Stock News | NASDAQ:AVBP | BenzingaMarch 21, 2025 | benzinga.comB. Riley Securities Initiates Coverage of ArriVent BioPharma (AVBP) with Buy RecommendationMarch 21, 2025 | msn.comArriVent BioPharma (NASDAQ:AVBP) Now Covered by Analysts at B. RileyB. Riley initiated coverage on shares of ArriVent BioPharma in a research note on Thursday. They set a "buy" rating and a $37.00 target price for the company.March 21, 2025 | marketbeat.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Recommendation of "Buy" from AnalystsShares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) have been assigned a consensus rating of "Buy" from the five ratings firms that are covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year taMarch 21, 2025 | marketbeat.comArriVent Biopharma initiated with a Buy at B. RileyMarch 20, 2025 | markets.businessinsider.comArriVent BioPharma (AVBP) Projected to Post Quarterly Earnings on ThursdayArriVent BioPharma (NASDAQ:AVBP) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to AnalystsMarch 19, 2025 | msn.comArriVent BioPharma (NASDAQ:AVBP) Trading Down 3.5% - Should You Sell?ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 3.5% - Time to Sell?March 18, 2025 | marketbeat.comArriVent BioPharma appoints PwC as new auditorMarch 15, 2025 | investing.comGuggenheim Initiates Coverage of ArriVent BioPharma (AVBP) with Buy RecommendationMarch 11, 2025 | msn.comArriVent Biopharma initiated with a Buy at GuggenheimMarch 10, 2025 | markets.businessinsider.comGuggenheim starts ArriVent Biopharma with a Buy on firmonertinib potentialMarch 10, 2025 | markets.businessinsider.comArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated by Analysts at GuggenheimGuggenheim assumed coverage on shares of ArriVent BioPharma in a research report on Monday. They set a "buy" rating and a $45.00 target price for the company.March 10, 2025 | marketbeat.comArriVent BioPharma's (AVBP) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $39.00 price objective on shares of ArriVent BioPharma in a research note on Friday.March 8, 2025 | marketbeat.comFY2025 Earnings Estimate for AVBP Issued By Lifesci CapitalArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Research analysts at Lifesci Capital dropped their FY2025 earnings per share estimates for shares of ArriVent BioPharma in a research report issued on Monday, March 3rd. Lifesci Capital analyst S. Slutsky now anticipates that the company willMarch 7, 2025 | marketbeat.comArriVent BioPharma, Inc.: Promising Clinical Trials and Market Potential Reinforce Buy RatingMarch 7, 2025 | tipranks.comArriVent BioPharma Reports 2024 Financial Results and Key AchievementsMarch 5, 2025 | msn.comArriVent BioPharma Reports 2024 Financial Results and ProgressMarch 3, 2025 | tipranks.comBuy Rating for ArriVent BioPharma: Promising Clinical Developments and Strategic Progress in NSCLC TreatmentMarch 3, 2025 | tipranks.comArriVent Biopharma sees cash runway into 2026March 3, 2025 | markets.businessinsider.comArriVent Biopharma reports FY24 EPS ($2.56), consensus ($2.69)March 3, 2025 | markets.businessinsider.comArriVent BioPharma (NASDAQ:AVBP) Posts Quarterly Earnings Results, Beats Expectations By $0.18 EPSArriVent BioPharma (NASDAQ:AVBP - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.18.March 3, 2025 | marketbeat.comArriVent BioPharma Reports Full Year 2024 Financial ResultsMarch 3, 2025 | globenewswire.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 9.1% in JanuaryArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 4,320,000 shares, a growth of 9.1% from the January 15th total of 3,960,000 shares. Based on an average daily volume of 159,500 shares, the short-interest ratio is currently 27.1 days. Currently, 22.2% of the shares of the company are short sold.February 17, 2025 | marketbeat.comArriVent Biopharma files automatic mixed securities shelfFebruary 4, 2025 | markets.businessinsider.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 13.1% in JanuaryArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) saw a large growth in short interest in January. As of January 15th, there was short interest totalling 3,810,000 shares, a growth of 13.1% from the December 31st total of 3,370,000 shares. Approximately 19.5% of the company's stock are short sold. Based on an average daily volume of 149,300 shares, the days-to-cover ratio is currently 25.5 days.February 1, 2025 | marketbeat.comArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu BiopharmaJanuary 24, 2025 | msn.comHC Wainwright Issues Optimistic Forecast for AVBP EarningsArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Research analysts at HC Wainwright increased their Q1 2025 earnings per share (EPS) estimates for ArriVent BioPharma in a research report issued on Wednesday, January 22nd. HC Wainwright analyst R. Burns now expects that the company will postJanuary 24, 2025 | marketbeat.comArriVent Biopharma price target raised to $39 from $36 at H.C. WainwrightJanuary 23, 2025 | finance.yahoo.comArriVent BioPharma’s Strategic Licensing and Partnerships Position It for Growth in ADC DevelopmentJanuary 22, 2025 | markets.businessinsider.comArriVent BioPharma’s Strategic Expansion and Promising Clinical Results Justify Buy Rating and Increased Price TargetJanuary 22, 2025 | markets.businessinsider.comArriVent bets big on experimental cancer drug with potential $1B licensing dealJanuary 22, 2025 | bizjournals.comArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $39.00HC Wainwright upped their price target on ArriVent BioPharma from $36.00 to $39.00 and gave the company a "buy" rating in a research note on Wednesday.January 22, 2025 | marketbeat.comArriVent BioPharma Expands Oncology Pipeline with New LicenseJanuary 22, 2025 | tipranks.comArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal CancersJanuary 21, 2025 | globenewswire.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest UpdateArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,810,000 shares, an increase of 13.1% from the December 15th total of 3,370,000 shares. Based on an average daily volume of 149,300 shares, the days-to-cover ratio is currently 25.5 days. Approximately 19.5% of the company's shares are sold short.January 18, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down - What's Next?ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down - Time to Sell?January 16, 2025 | marketbeat.com Remove Ads Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address AVBP Media Mentions By Week AVBP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVBP News Sentiment▼0.940.79▲Average Medical News Sentiment AVBP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVBP Articles This Week▼62▲AVBP Articles Average Week Remove Ads Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Xenon Pharmaceuticals News Today Amneal Pharmaceuticals News Today MoonLake Immunotherapeutics News Today Twist Bioscience News Today HUTCHMED News Today Mirum Pharmaceuticals News Today Vericel News Today Bausch Health Companies News Today Biohaven News Today Tarsus Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVBP) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVBP Stock Free AVBP Stock Alerts